This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TechnipFMC: A Strong Performer, But Is It Time to Buy the Stock?
by Zacks Equity Research
Despite its strengths, FTI's dividend yield of 0.67% lags its industry peers, making it less attractive to income-focused investors.
Is Core Stock Worth Buying After a 27% Surge in 6 Months?
by Zacks Equity Research
CLB stock is supported by international expansion, proprietary tech and solid cash flow amid competitive pricing, volatile oil prices and geopolitical tensions.
Why Is Core Laboratories (CLB) Down 16% Since Last Earnings Report?
by Zacks Equity Research
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are Options Traders Betting on a Big Move in Core Laboratories (CLB) Stock?
by Zacks Equity Research
Investors need to pay close attention to Core Laboratories (CLB) stock based on the movements in the options market lately.
CLB's Q4 Earnings Beat Estimates, Sales Lag, Expenses Increase
by Zacks Equity Research
Core Laboratories expects Reservoir Description revenues of $82-$85 million and Production Enhancement revenues of $39-$42 million for the first quarter of 2025.
Core Laboratories (CLB) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Core Laboratories (CLB) delivered earnings and revenue surprises of -4.35% and 1.27%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Core Laboratories to Post Q4 Earnings: Here's What to Expect
by Zacks Equity Research
CLB is expected to report higher revenues from the year-ago period's level. However, despite this revenue growth, the company is expected to face increased operating expenses.
Baker Hughes (BKR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Baker Hughes (BKR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Core Laboratories (CLB) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Hold Strategy is Apt for Core Laboratories Stock Now
by Zacks Equity Research
CLB benefits from strong international growth, high-margin projects and an efficient business model. However, stock underperformance, competition and U.S. market challenges pose risks.
Is Now the Right Time to Buy Core Laboratories After Its 12% YTD Rise?
by Zacks Equity Research
CLB shows strong earnings growth, solid cash flow and innovative technologies, but faces risks from geopolitical tensions, weak U.S. onshore activity and oil price volatility.
TechnipFMC Stock Rallies to 52-Week High: Buy, Hold or Sell?
by Zacks Equity Research
FTI's total backlog reached a high of $14.7 billion in Q3 2024, reflecting an 11.1% increase from the previous year.
Why Is Core Laboratories (CLB) Up 11.5% Since Last Earnings Report?
by Zacks Equity Research
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is the Options Market Predicting a Spike in CORE LABS INC (CLB) Stock?
by Zacks Equity Research
Investors need to pay close attention to CORE LABS INC (CLB) stock based on the movements in the options market lately.
Core Laboratories' Q3 Earnings and Sales Beat Estimates
by Zacks Equity Research
CLB expects Reservoir Description revenues of $87.5-$90.5 million and Production Enhancement revenues of $41-$45 million for the fourth quarter of 2024.
Core Laboratories (CLB) Q3 Earnings Match Estimates
by Zacks Equity Research
Core Laboratories (CLB) delivered earnings and revenue surprises of 0% and 1.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights ProPetro, Core Laboratories and Oceaneering
by Zacks Equity Research
ProPetro, Core Laboratories and Oceaneering are included in this Analyst Blog.
Energy Stocks to Watch Amid Q3 Earnings Despite Pricing Pressures
by Urbashi Dutta
Energy stocks such as PUMP, CLB and OII are poised to deliver a Q3 earnings beat.
TechnipFMC's (FTI) Q3 Earnings Preview: Things to Consider
by Zacks Equity Research
FTI beat the Zacks Consensus Estimate in each of the last four quarters, which resulted in an average earnings surprise of 24.5%.
Schlumberger (SLB) Beats Q3 Earnings Estimates
by Zacks Equity Research
Schlumberger (SLB) delivered earnings and revenue surprises of 1.14% and 1.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Core Laboratories Stock in Q3 Earnings?
by Zacks Equity Research
CLB is expected to report higher revenues compared with the previous quarter, along with reduced costs for services and product sales and general administrative expenses.
Can Core Laboratories (CLB) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Core Laboratories (CLB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Core Laboratories (CLB) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Core Laboratories (CLB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NNPC-Shell JV Agrees to Supply Gas to $3.3 Billion Methanol Project
by Zacks Equity Research
SHEL and its partners, including NNPC, join hands to supply gas to Brass Fertilizer to start a $3.3 billion project.
Here's Why Core Laboratories (CLB) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.